Psoriasis 銀屑病 Telegram group

Our current understanding considers psoriasis to be triggered by exogenous or endogenous environmental stimuli in genetically susceptible individuals. Such stimuli include group A streptococcal pharyngitis, viremia, allergic drug reactions, antimalarial drugs, lithium, beta-blockers, IFN-α withdrawal of systemic corticosteroids, local trauma (Köebner phenomenon), and emotional stress.

Additional studies have demonstrated that treatments that induce prolonged clearing of psoriatic lesions without continuous therapy, such as psoralen plus UVA irradiation, decreased the numbers of T cells in plaques by at least 90%. However, treatments that require continual therapy for satisfactory clinical results, such as cyclosporine and etretinate, simply suppress T-cell activity and proliferation.

In general, cost savings with biosimilars are less than those seen with generic small molecule agents. While cost reductions associated with small molecule generics can be 80% or higher, estimated biosimilar acquisition cost savings in the US have ranged from 10 to 40%. According to a 2017 estimate, the average cost for an 8-week supply of an infiximab biosimilar was 18% less than its reference product. Outside the US, cost savings on biosimilars are variable, ranging from as high as 70% in Norway (due to discounted government pricing) to 30% in India. Europe has approved 23 biosimilars, with an average price reduction of 20–30%.

While there are many potential triggers of psoriasis, infections are an important trigger and up to half of children with psoriasis have an exacerbation within 2 weeks following an upper respiratory infection. Psychological distress is a causative or maintaining factor in disease expression for many patients with psoriasis. Other well-documented triggers for fares include trauma, alcohol and smoking, as well as obesity. Plaque psoriasis is usually chronic with intermittent remissions. Plaques may persist for months to years at the same locations; however, periods of complete remission may occur.

At week 28, patients with ≥90% Psoriasis Area and Severity Index improvement from baseline (PASI 90) were rerandomized to withdrawal and received placebo (n = 182), or maintenance therapy (n = 193).
Efficacy in the guselkumab maintenance group was sustained through week 72, whereas efficacy diminished in the guselkumab withdrawal group (PASI 90, 86.0% vs. 11.5%).
After 20 weeks of retreatment, 80.4% of guselkumab withdrawal patients achieved PASI 90 responses versus baseline.

在第28週時為療效反應者 且於重新隨機分組後進入安慰劑組並退出TREMFYA®治療的受試 者中，喪失PASI 90療效反應的中位時間約為15週。

Chapter1 自體免疫疾病的起因
認識蛋白質、抗體的免疫系統
自體免疫疾病的3大促成因素
讓不良基因發作的腸漏症和麩質

Chapter2 導致免疫系統暴走的錯誤飲食
錯誤1〉營養不良的健康飲食！？
錯誤2〉傷害腸道的飲食
錯誤3〉發炎性和致免疫的食物
你終於搞懂了！

Chapter 3 讓免疫系統失控的生活方式
壓力爆表的緊張生活
亂了調的生理時鐘
睡得少又睡不好
動少動多都有害
一天吃幾餐也有影響
很多藥物都弊多於利
將一切拼湊起來

Chapter 4 你還有得救
站在巨人的肩上
一種全面的飲食和生活方案
與你的醫生配合
全心投入的時刻到了！

PART2 全面扭轉！保護你的免疫系統

Chapter 5 你究竟可以吃什麼？
肉類、家禽類和海鮮
蔬菜和水果
健康的脂肪
主要營養物質的比例
利用含有益生菌的食物
香料巡禮：可吃與不可吃
我能喝什麼？
關於食物的常見問題
各就各位，預備……

Chapter 6 你需要重新好好過日子
吃對食物也要吃對時間和方法
利用生理時鐘保護自己
進行足夠的低強度活動
一步一腳印

Chapter 7 正式踏上康復之路
這真的是治癒的良方嗎？
事前準備
度過第一個月
復原需要多長的時間？
要多嚴格才行？
獲得標準體重
常見Q&A

Chapter 8 你可能會遇到的困難
何時該進行疑難排解？
狀況1〉消化不良
狀況2〉無法耐受發酵食物
狀況3〉嚴重的小腸細菌過度生長
狀況4〉持續性感染及寄生蟲
狀況5〉腦腸軸──大腦讓腸道出問題
狀況6〉過敏、不耐受及敏感
狀況7〉器官功能支援的需求
狀況8〉更牢固有效的控制血糖
狀況9〉微量營養素匱乏
你的身體在修復腸道時需要協助嗎？
你的身體在控制免疫系統時需要協助嗎？
關於保健補充品的幾點備註

結語｜能不能重拾喜愛的食物？
何時可以開始重新引進食物？
如何重新引進食物？
重新引進食物的建議順序
為何我對從前習慣的食物反應如此劇烈？
迎接終身健康